News
Wed, 02 Nov 2022 05:32:00 -0400
Wed, 02 Nov 2022 05:32:00 -0400
Financial report for the period 1 January 2022 to 30 September 2022
|
PROFIT AND LOSS |
9M 2022 |
9M 2021 |
Growth as reported |
Growth at CER* |
|
USD million |
|
|
|
|
|
Net sales |
18,406 |
16,487 |
26% |
16% |
|
Operating profit |
8,245 |
7,242 |
28% |
14% |
|
|
|
|
|
|
|
Net profit |
5,990 |
5,931 |
14% |
N/A |
|
Diluted earnings per share (in USD) |
2.63 |
2.57 |
15% |
N/A |
|
* CER: Constant exchange rates (average 2021). |
|
|
|
|
Lars Fruergaard Jørgensen, president and CEO: "We are very pleased with the sales growth in the first nine months of 2022 which has enabled us to raise the outlook for the full year. The growth is driven by increasing demand for GLP-1-based diabetes treatments, especially Ozempic®. Within R&D, the encouraging phase 2 data with CagriSema in type 2 diabetes and the successful completion of the phase 3 programme for once-weekly insulin icodec support our aspiration of further raising the innovation bar for diabetes treatments."